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Background
According to recent studies about 1-3% of hypersensitivity
reactions are accompanied by skin eruptions. Among
these toxic epidermal necrolysis (TEN) and Stevens-
Johnson syndrome (SJS) are rare and the most severe
adverse cutaneous drug reactions that predominantly
involve the skin and mucous membranes. TEN and SJS
affecting approximately 1-4/1,000,000 annually with aver-
age reported mortality rate 25-35% (TEN), and 1-5% (SJS).
The aim of this work was to study the frequency of severe
bullous delayed allergic reactions, like TEN and SJS, their
clinical presentations, causative drugs, treatment and the
diagnostic approach required.
Method
We followed up 33 patients (7 males, 26 females) aged
21-80 years with various severe bullous dermatoses in
dermatology department of our hospital.
Results
Most of the patients had drug hypersensitivity reactions
(n=22) and most of them were female older than 70
years. 3 of them had TEN and 7 suffered from SJS. The
causative drugs of TEN and SJS were sulfonamides
(23%, n=5), NSAIDs (14%, n=3) and anticonvulsants (9%,
n=2). The most common drug was sulfamethoxazole
(18%). The most severe reactions were caused by sulfa-
methoxazole (13%), metamizole (4%) and carbamazepine
(9%). Mortality rate was about 4% (n=1).
Conclusion
The results of our study indicate that TEN and SJS may
occur in about 32% patients with severe bullous derma-
toses. Sulfanonamides, NSAIDs and anticonvulsants are
the most frequently implicated drugs. Diagnosis relies
mainly on clinical symptoms together with the results of a
skin biopsy. Due to the high risk of mortality, management
of patients with severe bullous dermatoses, especially TEN
and SJS, requires rapid identification and interruption of
the culprit drug, specialized supportive care and immuno-
modulatory therapy.
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